Phenylmethimazole decreases toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4114-4122

  Schwartz, Anthony L ^b   Malgor, Ramiro ^a   Dickerson, Eric ^a   Weeraratna, Ashani T ^c   Slominski, Andrzej ^d   Wortsman, Jacobo ^e   Harii, Norikazu ^a   Kohn, Aimee D ^f   Moon, Randall T ^g   Schwartz, Frank L ^a   Goetz, Douglas J ^b   Kohn, Leonard D ^a   McCall, Kelly D ^a,b  

^a OHIO UNIVERSITY   (United States)

^b Ohio University   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Cascade Cancer Center   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLMETHIMAZOLE; THIAMAZOLE; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; WNT5A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTITHYROID AGENTS; CELL LINE, TUMOR; CHEMOKINE CXCL10; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON-BETA; INTERLEUKIN-6; MELANOMA; METHIMAZOLE; MICE; MICE, NUDE; MICE, SCID; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; THIONES; TOLL-LIKE RECEPTOR 3; WNT PROTEINS;

EID: 67449156114     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0005     Document Type: Article

References (50)

1. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-3305 (Pubitemid 28023954)
2. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 2000;287:1606-1609 (Pubitemid 30127755)
3. Chan SK, Struhl G. Evidence that Armadillo transduces wingless by mediating nuclear export or cytosolic activation of Pangolin. Cell 2002;111:265-280 (Pubitemid 35292446)
4. Bienz M, Clevers H. Armadillo/β-catenin signals in the nucleus-proof beyond a reasonable doubt? Nat Cell Biol 2003;5:179-182
5. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000;16:279-283 (Pubitemid 30389591)
6. Iozzo RV, Eichstetter I, Danielson KG. Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 1995;55:3495-3499
7. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-288 (Pubitemid 41039152)
8. Saitoh T, Katoh M. Expression and regulation of WNT5A and WNT5B in human cancer: up-regulation of WNT5A by TNFα in MKN45 cells and up-regulation of WNT5B by β-estradiol in MCF-7 cells. Int J Mol Med 2002;10:345-349
9. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol 2003;56:280-285 (Pubitemid 37243920)
10. Shimizu H, Julius MA, Giarre M, Zheng Z, Brown AM, Kitajewski J. Transformation by Wnt family proteins correlates with regulation of β-catenin. Cell Growth Differ 1997;8:1349-1358 (Pubitemid 28008731)
11. Wong GT, Gavin BJ, McMahon AP. Differential transformation of mammary epithelial cells by Wnt genes. Mol Cell Biol 1994;14:6278-6286 (Pubitemid 24264457)
12. Olson DJ, Papkoff J. Regulated expression of Wnt family members during proliferation of C57 mg mammary cells. Cell Growth Differ 1994;5:197-206. (Pubitemid 24249672)
13. McCall KD, Harii N, Lewis CJ, et al. High basal levels of functional Toll-like receptor 3 (TLR3) and non-canonical Wnt5a are expressed in papillary thyroid cancer (PTC) and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 2007;148:4226-4237 (Pubitemid 47295676)
14. Underhill DM. Toll-like receptors: networking for success. Eur J Immunol 2003;33:1767-1775 (Pubitemid 37120847)
15. Anders HJ, Banas B, Schlondorff D. Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004;15:854-867 (Pubitemid 38375304)
16. Harii N, Lewis C, Vasko V, et al. Thyrocytes express a functional Toll-like receptor 3 (TLR3): overexpression can be induced by viral infection, reversed by phenylmethimazole, and is associated with Hashimoto's autoimmune thyroiditis. Mol Endocrinol 2005;19:1231-1250 (Pubitemid 40594121)
17. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006;16:32-37 (Pubitemid 43139707)
18. Rudofsky G, Jr., Reismann P, Witte S, et al. Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care 2004;27:179-183 (Pubitemid 38196729)
19. Kolek MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004;148:1034-1040 (Pubitemid 39646980)
20. Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today 2006;36:287-290 (Pubitemid 43288728)
21. Baumgarten G, Knuefermann P, Schuhmacher G, et al. Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. Shock 2006;25:43-49 (Pubitemid 43755985)
22. Baumgarten G, Knuefermann P, Wrigge H, et al. Role of Toll-like receptor 4 for the pathogenesis of acute lung injury in Gram-negative sepsis. Eur J Anaesthesiol 2006;23:1041-1048 (Pubitemid 44622933)
23. Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des 2006;12:4229-4245 (Pubitemid 44669751)
24. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376 (Pubitemid 37174535)
25. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005;224:203-212 (Pubitemid 40731528)
26. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 2005;11:3642-3646 (Pubitemid 40685579)
27. von Hafe P, Pina F, Perez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 2004;12:1930-1935
28. Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003;197:157-168 (Pubitemid 37485244)
29. Kim W, Lewis C, McCall K, et al. Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. J Endocrinol 2007;192:1-15. (Pubitemid 46638536)
30. Takeda K, Akira S. Toll receptors and pathogen resistance. Cell Microbiol 2003;5:143-153 (Pubitemid 36348031)
31. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-738 (Pubitemid 33009951)
32. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat Immunol 2003;4:161-167 (Pubitemid 36193018)
33. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-6672 (Pubitemid 36899248)
34. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate Toll-like receptor gene expression in viral infections. Genes Immun 2001;2:349-355 (Pubitemid 33674248)
35. Cheng G, Nazar AS, Shin HS, Vanguri P, Shin ML. IP-10 gene transcription by virus in astrocytes requires cooperation of ISRE with adjacent κB site but not IRF-1 or viral transcription. J Interferon Cytokine Res 1998;18:987-997 (Pubitemid 28565802)
36. Majumder S, Zhou LZ, Chaturvedi P, Babcock G, Aras S, Ransohoff RM. Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines. J Neurosci Res 1998;5:169-180 (Pubitemid 28469058)
37. Ohmori Y, Hamilton TA. The interferon-stimulated response element and a κB site mediate synergistic induction of murine IP-10 gene transcription by IFN-γ and TNF-α. J Immunol 1995;154:5235-5244
38. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-233
39. Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004;64:5632-5642 (Pubitemid 39095559)
40. Wen Z, Zhong Z, Darnell JE, Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241-250
41. Gartsbein M, Alt A, Hashimoto K, Nakajima K, Kuroki T, Tennenbaum T. The role of protein kinase Cδ activation and STAT3 Ser727 phosphorylation in insulin-induced keratinocyte proliferation. J Cell Sci 2006;119:470-481
42. Barboza JA, Wang S, Schaefer TS. Generation and characterization of a constitutively active Stat3 protein. Mol Biol Rep 2004;31:13-21. (Pubitemid 38250033)
43. Yeh YT, Ou-Yang F, Chen IF, et al. STAT3 Ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 2006;118:2943-2947
44. Zanger R, Novak R. Posttranslational elevation of cytochrome P450 3A levels and activity by dimethyl dulfoxide. Arch Biochem Biophys 1998;353:1-9. (Pubitemid 28373023)
45. Kohn LD, Goetz D, Benavides-Peralta U, et al., inventors. Compositions and methods for treatment of colitis. Patent 10/801,986; 2004
46. Kohn LD, Harii N, Benavides-Peralta U, et al, inventors. Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with Toll-like receptor overexpression. Patent 11/130,922;2005.
47. Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-α-dependent mechanism. Carcinogenesis 2008;29:1334-1342
48. Fujio Y, Matsuda T, Oshima Y, et al. Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS Lett 2004;573:202-206 (Pubitemid 39141058)
49. Dissanayake SK, Olkhanud PB, O'Connell MP, et al. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 2008;68:10205-10214
50. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003;300:1524-1525 (Pubitemid 36682871)